Company Performance Metrics
Gordion Bioscience has built a proprietary patient-derived dependency map across 20,000 genes and 26 cancer types - translating real tumor biology into pipeline decisions. Standard preclinical models (CRISPR screens, cell lines) systematically misrepresent the dependencies operating in patient tumors. Gordion's map is built entirely from tumor
biopsies, revealing what tumors actually depend on in human disease.
Platform applications: Target validation — distinguishing clinically translatable targets from cell-line artifacts. Combination strategy — identifying co-dependencies that limit monotherapy response (KRAS programs being a prime example). Bispecific design — functional co-dependency data from patient tumors, not inferred cell line biology.
Traction: Novel target against MTAP-mutated solid tumors licensed to Kohde Pharma (2025); first IO bispecific outlicensed (2026).
Proprietary portfolio: currently focusing on building a portfolio of Bi and Tri-specific antibodies for PDAC, CRC and NSCLC.
